BCL2 and diffuse large B-cell lymphoma: Despite the potential utility of BCL2 translocation analysis to help stratify patients with DLBCL for appropriate disease management (Hwang et al., 2001; Muris et al., 2006; Kendrick et al., 2014; Kawamoto et al., 2016), BCL2 translocation status is not considered to be a diagnostic biomarker of VRL.